Search Result

Results for "

Tetraxetan

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Linker (1) Biochemical Assay Reagents (5) Drug Derivative (1) Drug-Linker Conjugates for ADC (1) FAP (3) Peptide-Drug Conjugates (PDCs) (1) Radionuclide-Drug Conjugates (RDCs) (3) Reference Standards (1) Somatostatin Receptor (1)
By Research Areas:	Cancer (10)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W053583

*Tetraxetan* 1 Publications Verification DOTA	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Cancer
Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., ⁶⁸Ga, ¹¹¹In, ¹⁷⁷Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .

HY-147057

Rofapitide tetraxetan 2 Publications Verification FAP-2286	FAP	Cancer
Rofapitide tetraxetan (FAP-2286) is a potent and selective FAP-binding peptide with a mean IC₅₀ value of 2.7 nM for binding to FAP. Rofapitide tetraxetan can be labeled with radionuclides for diagnostic applications. Rofapitide tetraxetan has antitumor activity .

HY-117410

Vipivotide tetraxetan Maximum Cited Publications 17 Publications Verification PSMA-617	Drug-Linker Conjugates for ADC	Cancer
Vipivotide tetraxetan (PSMA-617) is a high potent prostate-specific membrane antigen (PSMA) inhibitor, with a K_i of 0.37 nM. Vipivotide tetraxetan (PSMA-617) is designed consisting of three components: the pharmacophore Glutamate-urea-Lysine, the chelator DOTA able to complex both 68Ga or 177Lu, and a linker connecting these two entities. Glutamate-urea-Lysine is the selective pharmacophore to bind to prostate specific membrane antigen.

HY-43869

*Vipivotide tetraxetan* Ligand-Linker Conjugate** PSMA-617 Ligand-Linker Conjugate	ADC Linker	Cancer
Vipivotide tetraxetan Ligand-Linker Conjugate (PSMA-617 Ligand-Linker Conjugate) is a complex composed of pharmacophore group Glutamate-urea-Lysine peptide coupling linker, which can be used to synthesize Vipivotide tetraxetan (PSMA-617). Glutamate-urea-Lysine selectively binds to prostate-specific membrane antigen (PSMA) .

HY-W053583R

Tetraxetan (Standard) DOTA (Standard)	Biochemical Assay Reagents Reference Standards Radionuclide-Drug Conjugates (RDCs)	Cancer
Tetraxetan (Standard) is the analytical standard of Tetraxetan (HY-W053583). This product is intended for research and analytical applications. Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., ⁶⁸Ga, ¹¹¹In, ¹⁷⁷Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .

HY-P10883

Lutetate tezuvotide tetraxetan	Biochemical Assay Reagents	Cancer
Lutetate tezuvotide tetraxetan is tetrahydrogenated Tetraxetan. Tetraxetan (DOTA) is a complexing agent that can be used to synthesize contrast agents in oncology medicine.

HY-P10905

Tezuvotide tetraxetan	Peptide-Drug Conjugates (PDCs)	Cancer
Tezuvotide tetraxetan is an antineoplastic peptide .

HY-147057A

*Rofapitide tetraxetan* acetate** FAP-2286 acetate	FAP	Cancer
Rofapitide tetraxetan (FAP-2286) acetate is a potent and selective FAP-binding peptide with a mean IC₅₀ value of 2.7 nM for binding to FAP. Rofapitide tetraxetan acetate can be labeled with radionuclides for diagnostic applications. Rofapitide tetraxetan acetate has antitumor activity .

HY-159526

Adarulatide tetraxetan DOTA-AE105	Biochemical Assay Reagents	Others
Copper adarulatidum tetraxetanum (Copper adarulatide tetraxetan) is a diagnostic imaging agent .

HY-158077

(R)-tetraMe-Tetraxetan (R)-tetraMe-DOTA	Biochemical Assay Reagents	Others
(R)-tetraMe-Tetraxetanis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. (R)-tetraMe-Tetraxetan can be used for conjugation of peptides and radionuclides.

HY-173374

DOTAGA-FAP-2286-ALB	FAP Drug Derivative	Cancer
DOTAGA-FAP-2286-ALB is a derivative of Rofapitide tetraxetan (HY-147057). DOTAGA-FAP-2286-ALB is a selective fibroblast activation protein (FAP) inhibitor with an IC₅₀ value of 67.5 nM. DOTAGA-FAP-2286-ALB enhances tumor retention via albumin interaction, prolonging blood circulation and improving radiometal complex stability (e.g., with ¹¹¹In and ²²⁵Ac). DOTAGA-FAP-2286-ALB is promising for research of radionuclide therapy (TRT) of FAP-positive solid tumors .

HY-P5128

DOTA-JR11 Satoreotide Tetraxetan	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research . DOTA-JR11 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

Cat. No.	Product Name	Type

HY-W053583

*Tetraxetan* 1 Publications Verification DOTA	Biochemical Assay Reagents
Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., ⁶⁸Ga, ¹¹¹In, ¹⁷⁷Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .

Tetraxetan

1 Publications Verification

DOTA

Biochemical Assay Reagents

Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., ⁶⁸Ga, ¹¹¹In, ¹⁷⁷Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .

HY-W053583R

Tetraxetan (Standard) DOTA (Standard)	Biochemical Assay Reagents
Tetraxetan (Standard) is the analytical standard of Tetraxetan (HY-W053583). This product is intended for research and analytical applications. Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., ⁶⁸Ga, ¹¹¹In, ¹⁷⁷Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .

Tetraxetan (Standard)

DOTA (Standard)

Biochemical Assay Reagents

Tetraxetan (Standard) is the analytical standard of Tetraxetan (HY-W053583). This product is intended for research and analytical applications. Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., ⁶⁸Ga, ¹¹¹In, ¹⁷⁷Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .

HY-158077

(R)-tetraMe-Tetraxetan (R)-tetraMe-DOTA	Chelators
(R)-tetraMe-Tetraxetanis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. (R)-tetraMe-Tetraxetan can be used for conjugation of peptides and radionuclides.

DOTA-JR11 Satoreotide Tetraxetan	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research . DOTA-JR11 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

Lutetate tezuvotide tetraxetan	Biochemical Assay Reagents	Cancer
Lutetate tezuvotide tetraxetan is tetrahydrogenated Tetraxetan. Tetraxetan (DOTA) is a complexing agent that can be used to synthesize contrast agents in oncology medicine.

Tezuvotide tetraxetan	Peptide-Drug Conjugates (PDCs)	Cancer
Tezuvotide tetraxetan is an antineoplastic peptide .

Adarulatide tetraxetan DOTA-AE105	Biochemical Assay Reagents	Others
Copper adarulatidum tetraxetanum (Copper adarulatide tetraxetan) is a diagnostic imaging agent .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.